First Patient Enrolled in Pridopidine Arm of the HEALEY ALS Platform Trial

First Patient Enrolled in Pridopidine Arm of the HEALEY ALS Platform Trial

282571

First Patient Enrolled in Pridopidine Arm of the HEALEY ALS Platform Trial

A pivotal clinical trial evaluating pridopidine for the treatment of amyotrophic lateral sclerosis (ALS) has enrolled its first participant, Prilenia Therapeutics, the medicine’s maker, announced. The Phase 2/3 study, dubbed HEALEY ALS Platform – Regimen D Pridopidine (NCT04615923), will compare the safety and effectiveness of pridopidine to placebo in an estimated 160 ALS patients, ages 18 and older. This study is one of four to date in the HEALEY ALS Platform trial (NCT04297683), which is…

You must be logged in to read/download the full post.